CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Scholar Rock Holding Corp is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Scholar Rock Holding Corp
301 BINNEY STREET, 3RD FLOOR
Phone: (857) 259-3860p:857 259-3860 CAMBRIDGE, MA  02142  United States Ticker: SRRKSRRK
Business Summary
Scholar Rock Holding Corporation is a biopharmaceutical company. The Company focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe and debilitating neuromuscular diseases. Its pipeline product candidates include apitegromab, a subcutaneous formulation of apitegromab, and SRK-439. The Apitegromab is an investigational fully human, intravenously administered monoclonal antibody designed to inhibit myostatin activation by selectively binding the pro- and latent forms of myostatin in the skeletal muscle. The SRK-439, is an investigational, subcutaneously administered fully human anti-pro/latent myostatin antibody that has high inhibitory potency while maintaining selectivity towards myostatin. Its early-stage pipeline includes additional programs for the treatment of patients with rare, severe, and debilitating neuromuscular diseases.
(Source: 6-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202512/31/2025YesYes--Yes

Industries
SIC Code Description
2836 Biological products, except diagnostic substances
8731 Commercial physical and biological research
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, Chief Executive Officer David L.Hallal 59 4/27/2025 7/1/2017
Chief Financial Officer VikasSinha 61 4/27/2025 4/27/2025
President - Research & Development, Director Akshay K.Vaishnaw 62 4/27/2025 5/21/2019
12 additional Officers and Directors records available in full report.

Business Names
Business Name
Scholar Rock Foreign Holdings, Inc. Delaware Scholar Rock Ireland Limited
Scholar Rock Germany GmbH
Scholar Rock Netherlands B.V.
5 additional Business Names available in full report.

General Information
Number of Employees: 289 (As of 2/24/2026)
Outstanding Shares: 114,883,096 (As of 2/26/2026)
Shareholders: 4
Stock Exchange: NASD
Federal Tax Id: 823750435
Fax Number: (302) 655-5049
Email Address: info@scholarrock.com


Copyright © 2026 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Sunday, April 12, 2026